Live
CellComplete biosynthesis of the anticancer cephalotaxinone and homoerythratineEndpoints NewsAmgen and the FDA want two different outcomes for Tavneos. What will patients do?Endpoints NewsEli Lilly invests in startup Abridge for clinical trial recruitmentBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-June 11, 2026FierceBiotech‘I wouldn’t call it a blip’: Biotech IPOs here to stay after another record-breaking listingBioWorldTakeda’s zasocitinib bests Sotyktu in phase III psoriasis trialEndpoints NewsEnliven prices $400M offering; Jazz drug Zepzelca fails confirmatory studyEndpoints NewsBiopharma's pay oddities of 2025: Executive perks and eccentricitiesFierceBiotechGuardant Health nabs FDA test approval to find patients for Boehringer’s new cancer drugFierceBiotechIpsen R&D chief on pipeline discipline, partnerships and 2026 milestonesPLoS BiologyIntAct-U-ExM enables super-resolution imaging of isoform-specific actin networks across species
PharmaVoice Apr 24, 2026

Is pharma missing the boat on diagnostics?

Is pharma missing the boat on diagnostics?

Original
Body unavailable. Use the original source.